Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggregation

Circulation. 1998 Jan 27;97(3):263-7. doi: 10.1161/01.cir.97.3.263.

Abstract

Background: Nitric oxide (NO) and related molecules are thought to inhibit human platelet aggregation by raising levels of cGMP.

Methods and results: Both oxidative stress (reactive oxygen species) and hemoglobin (Hb) seem to oppose NO effects. A major fraction of NO in the blood is bound to thiols of Hb, forming S-nitrosohemoglobin (SNO-Hb), which releases the NO group on deoxygenation in the microcirculation. Here we show that (1) both cell-free and intraerythrocytic SNO-Hb (SNO-RBC) inhibit platelet aggregation, (2) the oxidation state of the hemes in Hb influences the response--SNO-metHb (which is functionally similar to SNO-deoxyHb) has greater platelet inhibitory effects than SNO-oxyHb, and (3) the mechanism of platelet inhibition by SNO-Hb is cGMP independent.

Conclusions: We suggest that the RBC has evolved a means to counteract platelet activation in small vessels and the proaggregatory effects of oxidative stress by forming SNO-Hb.

MeSH terms

  • Blood Platelets / drug effects
  • Blood Platelets / metabolism
  • Cell-Free System
  • Cyclic GMP / blood
  • Dose-Response Relationship, Drug
  • Erythrocytes / chemistry
  • Erythrocytes / physiology
  • Hemoglobins / pharmacology*
  • Humans
  • Methemoglobin / administration & dosage
  • Methemoglobin / pharmacology
  • Oxyhemoglobins / pharmacology
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation / physiology
  • Platelet Aggregation Inhibitors / pharmacology*

Substances

  • Hemoglobins
  • Oxyhemoglobins
  • Platelet Aggregation Inhibitors
  • S-nitrosohemoglobin
  • Methemoglobin
  • Cyclic GMP